Relistor

Relistor is a brand name of methylnaltrexone, approved by the FDA in the following formulation(s):

RELISTOR (methylnaltrexone bromide - injectable; subcutaneous)

• 
  Manufacturer: PROGENICS
  
  Approval date: September 27, 2010
  
  Strength(s): 8MG/0.4ML
  

RELISTOR (methylnaltrexone bromide - solution; subcutaneous)

• 
  Manufacturer: PROGENICS
  
  Approval date: April 24, 2008
  
  Strength(s): 12MG/0.6ML (12MG/0.6ML) ^[RLD]

Has a generic version of Relistor been approved?

No. There is currently no therapeutically equivalent version of Relistor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relistor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
  Patent 6,559,158
  Issued: May 6, 2003
  Inventor(s): Joseph F.; Foss & Michael F.; Roizen & Jonathan; Moss & Chun-Su; Yuan & William; Drell
  Assignee(s): UR Labs, Inc.
  The University of Chicago
  A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
  
  Patent expiration dates:
  
  
  • November 3, 2017
    
    ✓ 
    Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 24, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Relistor Consumer Information (Drugs.com)
• Relistor Consumer Information (Wolters Kluwer)
• Relistor Consumer Information (Cerner Multum)
• Relistor Advanced Consumer Information (Micromedex)
• Relistor AHFS DI Monographs (ASHP)
• Methylnaltrexone Consumer Information (Wolters Kluwer)
• Methylnaltrexone Consumer Information (Cerner Multum)
• Methylnaltrexone Subcutaneous Advanced Consumer Information (Micromedex)
• Methylnaltrexone Bromide AHFS DI Monographs (ASHP)